Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19)
is limited. Objective To determine whether hydrocortisone improves outcome for …

Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …

BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …

Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized
with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment …

Interventions Patients were randomized to receive either open-label aspirin (n= 565), a
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …

IMPORTANCE: The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is
uncertain. OBJECTIVE: To determine whether antiplatelet therapy improves outcomes for …

… , Lauren Roberts, Justin Gillick, Catherine Roberts, Tehn Chin and Tina Lim-Chin as well
as Lee Hatherell, Khic-houy Prang, and Adrian Buzgau are acknowledged and appreciated. …

… – Dr Jason Thompson – Mr Adrian Buzgau – A/Prof Peter Smith …

… The authors would like to acknowledge Sue McLellan and Adrian Buzgau are thanked
for their assistance with the data extract. David Attwood from the TAC is thanked for his …